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Abstract
Objective—There is growing evidence for a link between energy and bone metabolism. The
nuclear receptor subfamily 5 member A2 (NR5A2) is involved in lipid metabolism and modulates
the expression of estrogen-related genes in some tissues. The objective of this study was to
explore the influence of NR5A2 on bone cells and to determine whether its allelic variations are
associated with bone mineral density (BMD).
Design—Analyses of gene expression by quantitative PCR and inhibition of NR5A2 expression
by siRNAs were used to explore the effects of NR5A2 in osteoblasts. Femoral neck BMD and 30
single nucleotide polymorphisms (SNPs) were first analyzed in 935 postmenopausal women and
the association of NR5A2 genetic variants with BMD was explored in other 1284 women in
replication cohorts.
Results—NR5A2 was highly expressed in bone. The inhibition of NR5A2 confirmed that it
modulates the expression of osteocalcin, osteoprotegerin, and podoplanin in osteoblasts. Two
SNPs were associated with BMD in the Spanish discovery cohort (rs6663479, P=0.0014, and
rs2816948, P=0.0012). A similar trend was observed in another Spanish cohort, with statistically
significant differences across genotypes in the combined analysis (P=0.03). However, the
association in a cohort from the United States was rather weak. Electrophoretic mobility assays
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and studies with luciferase reporter vectors confirmed the existence of differences in the binding
of nuclear proteins and the transcriptional activity of rs2816948 alleles.
Conclusions—NR5A2 modulates gene expression in osteoblasts and some allelic variants are
associated with bone mass in Spanish postmenopausal women.
Introduction
Epidemiological and experimental studies suggest a link between energy metabolism and
bone metabolism (1–3), which may also share genetic influences. For instance, Zhao et al.
(4) recently reported that polymorphisms at the osterix locus, a critical gene for osteoblast
development, are associated with childhood adiposity. The nuclear receptor subfamily 5
member A2 (NR5A2) is highly expressed in the liver and gastrointestinal tract and is
involved in the regulation of lipid metabolism (5). Moreover, it modulates the expression of
genes coding for aromatase and other enzymes participating in estrogen metabolism (6–8).
Therefore, we hypothesized that NR5A2 might play a role in skeletal homeostasis. The aims
of this study were to explore the influence of NR5A2 on bone cells and to analyze whether
the allelic variations in the NR5A2 gene are associated with bone mineral density (BMD).
Materials and methods
Analysis of gene expression in bone
Trabecular bone samples were obtained from the femoral heads of patients undergoing hip
arthroplasty for osteoarthritis (age 76±6 years, n=10) or fractures (age 77±4 years, n=9),
after obtaining informed written informed consent. They had no other disorders affecting
bone metabolism revealed by clinical examination and routine blood tests. The osteoblastic
cell line HOS-TE85 was obtained from EACC and maintained in Minimum Essential
Medium supplemented with antibiotics and 10% fetal bovine serum. RNA was isolated from
the bone pieces or confluent cell cultures and reverse transcribed with Superscript III reverse
transcriptase (Invitrogen- Life Technologies). Gene expression was analyzed by quantitative
real-time PCR using specific primers and Taqman probes (Applied Biosystems, Foster City,
CA, USA). The results were normalized by the expression of the constitutive gene TATA
box-binding protein (TBP). For comparison purposes, NR5A2 expression was also
measured in a human reference RNA mixture derived from ten different cell lines
(Stratagene, La Jolla, CA, USA).
NR5A2 inhibition
To explore the influence of NR5A2 on the transcription of other genes, we generated HOS-
TE85 clones with stable inhibition of NR5A2. Two different commercial plasmids coding
for shRNAS already validated for the specific inhibition of human NR5A2 gene expression
(TRCN0000019654 and TRCN0000019656) were purchased from Sigma–Aldrich. The viral
particles were prepared according to the manufacturer’s protocol. The amount of viruses
necessary for obtaining a 50% infection of HOS-TE85 cultures was determined by using
GFP-encoding viruses. A similar amount of NR5A2 shRNA viruses was used for infecting
HOS-TE85 cultures grown to 50% confluence. Puromycin (1.5 μg/ml) was added to the
cultures 48 h after infection and ten resistant clones were selected after several medium
changes and were used in subsequent experiments. The studies of the effect of NR5A2
inhibition on the expression of other osteoblastic genes were done with two of them,
resulting from the infection with virus prepared from TRCN0000019656. They were
cultured in the presence or absence of 1,25-dihydroxyvitamin D3 (10−8 M), a well-known
stimulus for the osteocalcin gene. HOS-TE85 clones infected with virus preparations
derived from plasmid pLKO.1-TRC control (Sigma) were used as a negative control. Gene
expression was analyzed using specific primers and Taqman probes (Applied Biosystems).
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The results were normalized by the expression of the constitutive gene TBP. Experiments
were repeated three times.
Electrophoretic shift and reporter vector assays
Nuclear extracts were prepared from subconfluent HepG2 cell cultures. Binding reactions
and electrophoresis mobility shift assays (EMSA) were performed as described previously
(9), using two 20 nt-long, 5′-fluorescein-labeled, double-stranded oligonucleotides
including either C or G alleles of the rs2816948 polymorphism and the surrounding region.
Gel analysis was carried out in an FLA-5100 fluorescent image analyzing system (FujiFilm).
Competition studies were carried out with an unlabeled C allele-specific oligo-nucleotide.
The specificity of the retarded band was tested by adding a 50-fold excess of an unrelated
oligonucleotide to the reaction mix.
For the construction of luciferase reporter plasmids, a 248 bp fragment of the NR5A2 gene
promoter extending from position −212 to position +36 was amplified by PCR using primers
modified to contain KpnI and XhoI sites and cloned in pGEMT-easy vector (Promega),
subcloned into the promoterless pGL3- basic vector (Promega) and then used in subsequent
transient transfection assays of HepG2 cultures. The procedures for transfection and
measurement of luciferase activity have been described previously (10).
Genetic association study
Discovery cohort—We selected 935 Caucasian post-menopausal women over 50 years of
age (range 50–88, mean 66) living in Cantabria, a region in Northern Spain. They included
volunteers recruited by advertisements, taking part in a population study on the
epidemiology of osteoporosis, and women sent to our clinic because of osteoporosis
concerns. Participants gave informed consent and the study was approved by the Clinical
Research Ethics Committee of the Hospital U.M. Valdecilla. Women with diseases that
might potentially affect bone metabolism were excluded. These diseases/conditions included
chronic disorders involving vital organs (e.g. heart, lung, liver, and kidney), serious
metabolic diseases (e.g. hypo- and hyper-parathyroidism, hyperthyroidism, etc.), skeletal
diseases other than primary osteoporosis (e.g. Paget disease, osteogenesis imperfecta,
rheumatoid arthritis, etc.), and use of drugs affecting bone metabolism (e.g. hormone
replacement therapy, corticosteroids, anticonvulsant drugs, and anti-resorptive drugs). In
addition, women with non-Spanish ancestors were excluded (11). BMD was measured with
a Hologic densitometer. Results at the femoral neck are reported, which had a coefficient of
variation of 1.4% in normal subjects after repositioning.
Tagging single nucleotide polymorphisms (SNPs) covering the common variations of the
NR5A2 gene, as well as the 16 kb upstream and downstream regions, and with a minor
allele frequency >5% were selected with Tagger Software http://www.broadinstitute.org/
mpg/tagger. SNPs with a potential regulatory role suggested by bioinformatic analyses
(Math Inspector http://www.genomatix.de and, Mapper http://www.mapper.chip.org) were
also included. DNA was isolated from peripheral blood and a 30 SNP set was analyzed by
iPlex technology on a Mass-Array platform (Sequenom, Hamburg, Germany) or by using
Taqman assays. Reproducibility was confirmed by obtaining consistent genotypes in 30
replicate samples.
Replication cohorts—The Valencia cohort included 324 Caucasian postmenopausal
women aged 41–69 years (mean 52) attending a menopause clinic and living in Valencia, a
region in eastern Spain. BMD was measured using either a Lunar or a Norland densitometer.
The results obtained from different densitometers were standardized as proposed by Lu et al.
(12).
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The Kansas City cohort included 930 unrelated Caucasian postmenopausal women aged 45–
87 years (mean 65), recruited from Midwestern U.S. (mainly in Kansas City and vicinity
areas) (13). BMD was measured at the femoral neck using a Hologic densitometer. Alleles
of 50 polymorphisms of the NR5A2 region were extracted from a Genomewide Association
Study (GWAS) with the Affymetrix Human SNP Assay 6.0 to carry out an in silico
replication.
Exclusion criteria in the Kansas City and Valencia cohorts were similar to those in the
discovery cohort. Studies were approved by the Institutional Review Committees. Informed
consent was obtained from the participants.
Statistical analyses
The Hardy–Weinberg equilibrium (HWE) and the association of alleles with BMD were
studied at the single-locus level and adjusted by age and weight as covariates using Plink
(14) and SPSS Software (SPSS, Chicago, IL, USA). Haplotypic blocks were built by the
method of Gabriel, implemented in Haploview (15). The association between haplotypes
and BMD was explored by testing 2-SNP haplotypes using the sliding window procedure, as
well as haplotypes including SNPs that were part of a single haplotypic block. Multiple test
correction was performed with the software developed by Nyholt (16). Power analysis was
done using Quanto Software (available at http://hydra.usc.edu/gxe/). We estimated a 86%
power to detect a polymorphism explaining at least 1% of the BMD variance under an
additive model (approximately equivalent to a 0.25 S.D. difference between opposite
homozygotes) in the discovery cohort.
Results
NR5A2 is expressed in bone and modulates gene expression in osteoblasts
Abundant NR5A2 transcripts (up to 1000-fold in comparison with the reference RNA) were
detected in all bone samples. They tended to be slightly more abundant in fracture samples
than in controls, but the difference was not statistically significant (P=0.2, not shown). In
order to investigate the potential effects of NR5A2 in osteoblasts, we generated HOS-TE85
clones with stable inhibition of NR5A2 expression, down to 9±2% of the controls. NR5A2
inhibition resulted in a marked increase in osteoprotegerin and osteocalcin expression, up to
tenfold, both in basal cultures and in 1,25-dihydroxyvitamin D3 cultures (Fig. 1). On the
other hand, the expression of podoplanin was markedly inhibited (Fig. 1) and there were
inconsistent effects on other genes, such as alkaline phosphatase, estrogen receptors, LRP5,
LRP6, and FRZB. The baseline expression of aromatase in HOS-TE85 cells was low and
tended to decrease slightly with NR5A2 inhibition. On the contrary, aromatase expression
was increased by NR5A2 inhibition in 1,25-dihydroxyvitamin D3-stimulated cultures (not
shown). The gene encoding aromatase has several alternative promoters and first exons. In
bone tissue samples, NR5A2 expression was correlated with total aromatase transcripts and
with I.4-containing transcripts, which is the major form of first exon found in bone (Fig. 2).
Association of NR5A2 polymorphisms with bone mass
Three out of the 30 SNPs did not follow HWE. The remaining 27 SNPs were included in the
analysis (Table 1). The average genotyping rate was 97.9%. Polymorphisms were grouped
into seven haplotypic blocks. Five SNPs were associated with femoral neck BMD at the
nominal P value of 0.05 (Fig. 3). The strongest association was found with three SNPs
within the first haplotypic block, at positions 198247395–198295054. Two of them were
associated with BMD with P values below the multiple-test corrected threshold of 0.0026:
rs6663479 (P=0.0014) and rs2816948 (P=0.0012). The haplotypic analysis confirmed the
results of the single-locus analysis. SNP pairs showing a significant association with BMD
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are depicted in Fig. 3. Likewise, haplotypes including the three SNPs in block 1 or the five
SNPs in block 5 were also associated with BMD (P=0.0013 and 0.0160 respectively).
Similar results were found after age and weight adjustment (not shown).
Three SNPs with the most significant P values (rs6663479, rs2816937, and rs2816948) were
genotyped in a different cohort of postmenopausal women from Valencia (Eastern Spain).
There was a trend for similar BMD differences across rs6663479 and rs2816948 genotypes.
The latter are shown in Table 2.
The NR5A2 rs2816948 polymorphism was not included in the Affymetrix Human SNP
Assay 6.0 used to genotype Kansas City cohort. In this cohort, we found one SNP,
rs2821320, located at position chromosome 1: 198331838 (build 36), marginally associated
with femoral neck BMD (P=0.04; Fig. 4).
Polymorphisms of NR5A2 promoter influence protein binding and transcriptional activity
EMSA suggested a difference in the ability of rs2816948 alleles to bind nuclear proteins.
Competition experiments carried out with nonspecific oligonucleotides revealed the
presence of a specific binding. The band intensity of the G allele was on average 53±14% of
the intensity of that of the C allele (P=0.016) and disappeared very easily when competed
with increasing amounts of an unlabeled C-specific oligonucleotide (Fig. 5A) Also, the
luciferase assays showed that the C to G change resulted in a 24% decrease in the activity of
the promoter (P<0.005; Fig. 5B).
Discussion
We have shown that NR5A2 is highly expressed in bone and modulates the expression of
some osteoblastic genes, thus suggesting that NR5A2 may play a role in skeletal
homeostasis.
BMD is a trait with a strong genetic component (17). Genomewide association studies
searching for genes associated with BMD have identified several loci at genes known to
influence bone metabolism, such as estrogen receptors, osteoprotegerin, lipoprotein
receptor-related protein, or sclerostin (18–21). Candidate gene studies have refined the gene
regions involved in the association (22). However, the combined effect of those loci explains
only a minor proportion of BMD variation in the population. Therefore, much more research
is needed to elucidate the genetic factors underlying the hereditary influence on BMD. We
found that several SNPs in the 5′ region of the NR5A2 gene were associated with BMD.
Among them, the rs2816948 polymorphism showed that allelic differences in the interaction
with nuclear proteins and the transcriptional activity of reporter gene constructs. C allele,
which displayed higher transcriptional activity, was associated with lower BMD, suggesting
that the net result of NR5A2 effect is to decrease bone mass. Consistent with this idea, there
was a nonsignificant trend for higher NR5A2 expression in bone samples from patients with
hip fractures than in control samples from osteoarthritic patients. The inhibition of NR5A2
resulted in increased expression of osteocalcin and osteoprotegerin, thus suggesting that
NR5A2 tends to decrease both factors. Osteocalcin is a well-known marker of differentiated
osteoblast function, whereas osteoprotegerin is an inhibitor of osteoclast differentiation.
Therefore, NR5A2 might inhibit bone formation and stimulate bone resorption. NR5A2
modulates the expression of aromatase and estrogen receptors in some tissues (6, 8, 23).
However, the inhibition of NR5A2 had inconsistent effects on the expression of these genes
in the osteoblastic cell line HOS-TE85. Therefore, further studies are needed to clarify
whether NR5A2 actually regulates estrogen-related genes in bone.
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Genetic association studies have a number of drawbacks, including the difficulty to
distinguish between true and casual associations, due to chance, population stratification, or
genotyping errors. Decreasing the P value threshold for significance helps to reduce the
number of false associations but increases type II error. The replication in different cohorts
and functional studies are other approaches to identify true associations. Nevertheless, a
number of factors may hamper the replication of true genetic association data (24). Our in
vitro studies support the regulatory role of the upstream rs2816948 polymorphism.
However, the association was only partially replicated in other cohorts. Alleles at the
rs2816948 locus tended to be associated with BMD in the same direction in the two Spanish
cohorts, and in fact, they were significant in the global analyses and in the Cantabria cohort,
but not in the Valencia cohort, perhaps due to the smaller number of women included. This
SNP was not studied in the Kansas City cohort, but other SNPs in the region were not
associated with BMD. The role of population differences and environmental influences in
those results in presently unclear, but it is interesting to notice that a weak association
between BMD and a NR5A2 SNP was reported in a GWAS of other North American
population (25).
In conclusion, NR5A2 gene is expressed in bone and modulates gene expression in
osteoblasts. Some common polymorphisms in the 5′-region of the gene, which show allelic
differences in functional assays in vitro, are associated with femoral neck BMD in Spanish
postmenopausal women. These results suggest that the allelic variations in the NR5A2 gene
may contribute to explain the genetic influence on bone mass, thus pointing toward NR5A2
as a novel osteoporosis candidate gene.
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Figure 1.
Gene expression in unstimulated and 1,25-dihydroxyvitamin D3-stimulated HOS-TE85
osteoblastic cells. The results represent the mean and S.D. of gene expression in two clones
with stable inhibition of NR5A2, shown as the percentage of gene expression in
unstimulated control cells. Similar results were obtained in three independent experiments.
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Figure 2.
Relationship between NR5A2 and aromatase expression in bone samples (A, total
aromatase; B, I.4-transcripts). Arbitrary units after normalization by TBP expression.
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Figure 3.
Association of NR5A2 polymorphisms with femoral neck BMD in the Cantabria cohort. P
values for the single-locus and haplotypic analyses (only significant haplotypes are shown).
The haplotypic structure of the NR5A2 gene is also shown. Full colour version of this figure
available via http://dx.doi.org/10.1530/EJE-11-0571.
Riancho et al. Page 11
Eur J Endocrinol. Author manuscript; available in PMC 2013 June 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4.
Association of NR5A2 polymorphisms with femoral neck BMD in postmenopausal women
of the Kansas City cohort. The chromosome position of the SNPs included in the array is
shown in the horizontal axis (from 198247394 through 198429625, which is the region
explored in the discovery cohort with the SNPs included in Fig. 3).
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Figure 5.
Functional studies. (A) The six lanes on the left correspond to experiments done with a
labeled oligonucleotide specific for allele C of the rs2816948 polymorphism, whereas in the
six lanes on the right a labeled oligonucleotide specific for allele G was used. NE indicates
that no extract was added to the labeled probe. In lanes labeled C and G, nuclear extracts
were added to labeled C- and G-specific probes respectively. In lanes labeled 10×, 25×, and
50×, a 10-, 25-, and 50-fold excess of an unlabeled C-specific oligonucleotide was used for
interfering the formation of the complexes by either C-specific or G-specific probes. In the
lanes labeled as NS, a 50-fold excess of a nonspecific probe was used for competition. The
specific complex is indicated with an arrow. (B) Differences in the transcriptional activities
of C- and G-specific fragments when cloned in a luciferase reporter vector. The results are
the average of four different experiments (***P<0.005).
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Table 2
Standardized femoral neck BMD (g/cm2), according to rs2816948 genotypes in Spanish cohorts. Mean±S.D.
(n).
GG GC CC P value
Cantabria 0.829±0.101 (21) 0.804±0.129 (228) 0.777±0.123 (657) 0.0012
Valencia 0.833±0.216 (6) 0.792±0.110 (66) 0.806±0.114 (252) NS
Global 0.830±0.130 (27) 0.801±0.125 (294) 0.785±0.121 (909) 0.03
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